Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

Brown University

2007, Providence, RI

Residency

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

2014, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Stacy Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in our current standards of medical practice.

Dr. Croteau currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.

Publications

  1. 2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. Am J Hematol. 2025 Apr; 100(4):666-684. View Abstract

  2. A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors. Res Pract Thromb Haemost. 2025 Jan; 9(1):102693. View Abstract

  3. The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia. J Pediatr. 2024 Sep; 272:114089. View Abstract

  4. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024 Apr; 30 Suppl 3:39-44. View Abstract

  5. Corrigendum to 'Evaluation of Venous Thromboembolism Risk Factors Reveals Subtype Heterogenicity in Children with Central Venous Catheters: A Multi-Center Study from the CHAT Consortium' [Journal of Thrombosis and Haemostasis 21/9 (2023) 2441 - 2450]. J Thromb Haemost. 2023 Dec; 21(12):3658. View Abstract

  6. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023 May; 7(4):100179. View Abstract

  7. Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children's Hospital Acquired Thrombosis consortium. J Thromb Haemost. 2023 09; 21(9):2441-2450. View Abstract

  8. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023 03; 16(sup1):107-127. View Abstract

  9. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 12 27; 6(24):6140-6150. View Abstract

  10. Hemophilia A/B. Hematol Oncol Clin North Am. 2022 08; 36(4):797-812. View Abstract

  11. Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients. Am J Surg Pathol. 2022 07 01; 46(7):963-976. View Abstract

  12. Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. Haemophilia. 2022 May; 28(3):453-461. View Abstract

  13. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. Pediatr Crit Care Med. 2022 01 01; 23(1):e1-e9. View Abstract

  14. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. J Manag Care Spec Pharm. 2022 Apr; 28(4):449-460. View Abstract

  15. Utility of Blood Cultures and Empiric Antibiotics in Febrile Pediatric Hemophilia Patients With Central Venous Access Devices. Pediatr Emerg Care. 2021 Dec 01; 37(12):e1531-e1534. View Abstract

  16. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021 11 18; 385(21):1961-1973. View Abstract

  17. Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. J Thromb Haemost. 2022 01; 20(1):133-137. View Abstract

  18. Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor. J Thromb Haemost. 2021 11; 19(11):2702-2709. View Abstract

  19. The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia. 2021 Sep; 27(5):802-813. View Abstract

  20. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. View Abstract

  21. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm. 2021 Mar; 27(3):316-326. View Abstract

  22. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27(2):211-220. View Abstract

  23. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021 Jan; 27(1):49-59. View Abstract

  24. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev. 2021 05; 47:100759. View Abstract

  25. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2021 01; 96(1):128-144. View Abstract

  26. Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 01; 228:252-259.e1. View Abstract

  27. Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. Haemophilia. 2021 Mar; 27(2):e270-e273. View Abstract

  28. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020 08; 95(8):960-965. View Abstract

  29. Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. Pediatr Blood Cancer. 2020 09; 67(9):e28497. View Abstract

  30. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia. 2020 May; 26(3):e128-e129. View Abstract

  31. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 07; 43(4):880-890. View Abstract

  32. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost. 2020 Feb; 4(2):326-333. View Abstract

  33. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clin Pharmacokinet. 2020 02; 59(2):245-256. View Abstract

  34. Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia. 2020 Jan; 26 Suppl 1:3-19. View Abstract

  35. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv. 2019 12 23; 3(24):4166-4176. View Abstract

  36. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020 Jan; 26(1):56-63. View Abstract

  37. Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. Pediatr Blood Cancer. 2020 01; 67(1):e28004. View Abstract

  38. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019; 10:335-340. View Abstract

  39. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675. View Abstract

  40. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 03; 25(2):e126-e129. View Abstract

  41. Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. Am J Hematol. 2018 Jun 08. View Abstract

  42. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018 07; 16(7):1437-1441. View Abstract

  43. Evolving Complexity in Hemophilia Management. Pediatr Clin North Am. 2018 06; 65(3):407-425. View Abstract

  44. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2(3):607-614. View Abstract

  45. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res Pract Thromb Haemost. 2018 Jul; 2(3):535-548. View Abstract

  46. Fifth Åland Island conference on von Willebrand disease. Haemophilia. 2018 May; 24 Suppl 4:5-19. View Abstract

  47. The spectrum of bleeding in women and girls with haemophilia B. Haemophilia. 2018 Mar; 24(2):180-185. View Abstract

  48. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr. 2017; 5:68. View Abstract

  49. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia. 2017 Mar; 23(2):e93-e98. View Abstract

  50. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016 12; 91(12):1252-1260. View Abstract

  51. The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. Semin Cutan Med Surg. 2016 Sep; 35(3):147-52. View Abstract

  52. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatr Blood Cancer. 2016 10; 63(10):1822-8. View Abstract

  53. Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. Pediatr Blood Cancer. 2016 Mar; 63(3):499-503. View Abstract

  54. Author's response: 'Transition considerations for extended half-life factor products'. Haemophilia. 2015 Sep; 21(5):e454-5. View Abstract

  55. Transition considerations for extended half-life factor products. Haemophilia. 2015 May; 21(3):285-288. View Abstract

  56. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View Abstract

  57. Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? Haemophilia. 2015 Mar; 21(2):190-195. View Abstract

  58. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr. 2014 Feb; 164(2):383-8. View Abstract

  59. Novel dominant ß-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)]. Pediatr Blood Cancer. 2013 Oct; 60(10):E131-4. View Abstract

  60. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5. View Abstract

  61. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013 Jan; 162(1):142-7. View Abstract
BESbswy